 NEW YORK LONDON PARIS--BUSINESS WIRE-- MRSA--Regulatory News: Aptorum Group Limited Nasdaq: APM, Euronext Paris: APM Aptorum Group or Aptorum, a clinical-stage biopharmaceutical company, announces further positive results of its ongoing Phase 1 clinical trial for ALS-4 a first in-class anti-virulence approach based small molecule targeting Staphylococcus aureus, including, but not limited to Methicillin Resistant Staphylococcus Aureus MRSA. Specifically, two additional cohorts Coh 